Insider Trading History of Meglasson Martin

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Meglasson Martin since 2006. The trader's CIK number is 1280564. At the time of the last reporting, Meglasson Martin was the V-P, Discovery Resea of Bellerophon Therapeutics, Inc.. (stock ticker symbol BLPH). Also see all insider trading activities at Bellerophon Therapeutics, Inc..

Note that in the past MEGLASSON MARTIN also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Ligand Pharmaceuticals Inc (LGND) by Meglasson Martin

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2010 LGND 6,250 $10,187 0 $0 0 $0
2008 LGND 3,000 $10,077 0 $0 0 $0
2007 LGND 2,000 $12,390 0 $0 0 $0
2006 LGND 0 $0 5,313 $59,654 5,313 $38,519

Yearly summary of insider trading at Bellerophon Therapeutics, Inc. (BLPH) by Meglasson Martin

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2015 BLPH 12,712 $149,980 0 $0 0 $0


Insider trading activities at 2 companies by Meglasson Martin:

1. Ligand Pharmaceuticals Inc (LGND)

2. Bellerophon Therapeutics, Inc. (BLPH)

Table 1. Insider trading of Ligand Pharmaceuticals Inc (LGND) by Meglasson Martin

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2010-05-11 LGND Buy 6,250 1.63 10,187
2008-05-09 LGND Buy 3,000 3.36 10,077
2007-08-30 LGND Buy 2,000 6.20 12,390
2006-12-15 LGND Sale 5,313 11.23 59,654
2006-12-15 LGND Option Ex 5,313 7.25 38,519

Table 2. Insider trading of Bellerophon Therapeutics, Inc. (BLPH) by Meglasson Martin

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2015-05-20 BLPH Buy 712 8.40 5,980
2015-02-19 BLPH Buy 12,000 12.00 144,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Meglasson Martin (V-P, Discovery Resea of Bellerophon Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.